CD274 and non-small cell lung carcinoma: In one study, patients with NSCLC who either had primary or acquired resistance to prior anti-PD-1 or anti-PD-L1 monotherapy, then received durvalumab IV 20 mg/kg every 4 weeks and tremelimumab IV 1 mg/kg every 4 weeks.